0000000000916294

AUTHOR

R. Noguera Salvá

showing 2 related works from this author

Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.

2021

Abstract Introduction Renal cell carcinoma (RCC) accounts for 2–3% of all tumors being the most frequent solid lesion in the kidney. Objective To determine what genetic alterations and immunohistochemical (IHC) of clear cell renal carcinoma (ccRCC) are associated with prognosis and tumor aggressiveness. Patients and Methods Experimental analytical study with 57 patients who underwent radical and partial nephrectomy between 2005 and 2011, all with diagnosis of ccRCC and minimum post-operative follow-up of 36 months. The pathological study included IHC determination of biomarkers associated (CAIX, CAM 5.2, CD10, c-erbB-2, EGFR, HIF-1a, Ki67, MDM2, PAX-2 y 8, p53, survivin and VEGFR 1 and 2). …

p530301 basic medicineMaleCancer Researchmedicine.medical_treatmentGastroenterologyNephrectomy0302 clinical medicineFHITRenal cell carcinomaCDKN2ANeoplasm MetastasisClear cell renal carcinomaRC254-282KidneyBRCA1 y 2Neoplasms. Tumors. Oncology. Including cancer and carcinogensCDKN2A: cyclin-dependent kinase Inhibitor 2AMiddle AgedPrognosisImmunohistochemistryNephrectomyKidney NeoplasmsMLPATumor BurdenSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.medical_specialty03 medical and health sciencesInternal medicinemedicineHumansMultiplex ligation-dependent probe amplificationCarbonic Anhydrase IXSurvival rateCarcinoma Renal CellAgedNeoplasm Stagingbusiness.industryCAIXmedicine.disease030104 developmental biologyNeoplasm GradingNeoplasm Recurrence LocalbusinessTranscriptomeFollow-Up StudiesCancer treatment and research communications
researchProduct

Perfil genómico del neuroblastoma de alto riesgo mediante hibridación genómica comparada

2006

El neuroblastoma presenta alteraciones genéticas que predicen su evolución clínica. Ganancias cromosómicas completas están asociadas a estadios clínicos no avanzados y evolución favorable, mientras que pérdidas de 1p, ganancia de 17q y amplificación del gen MYCN (MNA) son indicativas de estadios clínicos avanzados y pronóstico desfavorable. Son neuroblastomas de alto riesgo (NB-HR) los presentes en niños mayores de un año: estadio 4 o MNA en cualquier estadio de enfermedad, excluyendo estadio 1. El pronóstico de estos enfermos es malo, incluso con tratamientos agresivos. Sólo MNA confiere valor pronóstico negativo. Se remitieron al Centro de Referencia Nacional del neuroblastoma 60 casos de…

OncologyComparative genomic hybridizationmedicine.medical_specialtyBiological studiesmedicine.diagnostic_testbusiness.industryFluorescence in situ hybridizationClinical courseIn situ hybridizationmedicine.diseasePediatricsRJ1-570NeuroblastomaInternal medicineNeuroblastomaMYCNPediatrics Perinatology and Child Healthmedicine1p DeletionStage (cooking)businessFluorescence in situ hybridizationComparative genomic hybridizationAnales de Pediatría
researchProduct